CYP19A1 and breast cancer: Metformin inhibited aromatase expression and thus the potential efficacy of a combination of metformin and letrozole was evaluated in a phase II randomized clinical trial in postmenopausal patients with ER-positive BC (NCT01589367) [45, 46].